Publication: Tumoral heterogeneity in neuroblastoma
dc.contributor.author | Gomez, Roshna Lawrence | |
dc.contributor.author | Ibragimova, Shakhzada | |
dc.contributor.author | Ramachandran, Revathy | |
dc.contributor.author | Ali, Fahad R | |
dc.date.accessioned | 2023-04-25T08:09:08Z | |
dc.date.available | 2023-04-25T08:09:08Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Abstract: Neuroblastoma is a solid, neuroendocrine tumor with divergent clinical behavior ranging from asymptomatic to fatal. The diverse clinical presentations of neuroblastoma are directly linked to the high intra- and inter-tumoral heterogeneity it presents. This heterogeneity is strongly associated with therapeutic resistance and continuous relapses, often leading to fatal outcomes. The development of successful risk assessment and tailored treatment strategies lies in evaluating the extent of heterogeneity via the accurate genetic and epigenetic profiling of distinct cell subpopulations present in the tumor. Recent studies have focused on understanding the molecular mechanisms that drive tumoral heterogeneity in pursuing better therapeutic and diagnostic approaches. This review describes the cellular, genetic, and epigenetic aspects of neuroblastoma heterogeneity. In addition, we summarize the recent findings on three crucial factors that can lead to heterogeneity in solid tumors: the inherent diversity of the progenitor cells, the presence of cancer stem cells, and the influence of the tumor microenvironment. | en_US |
dc.identifier.other | 204-2022.129 | |
dc.identifier.uri | https://repository.mbru.ac.ae/handle/1/1171 | |
dc.language.iso | en | en_US |
dc.subject | Neuroblastoma | en_US |
dc.subject | Heterogeneity | en_US |
dc.subject | Tumor Origin | en_US |
dc.subject | Cancer Stem Cell | en_US |
dc.subject | Tumor Microenvironment | en_US |
dc.title | Tumoral heterogeneity in neuroblastoma | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | en_US |